Show simple item record

dc.contributor.authorAndo, Koji
dc.contributor.authorShah, Ankur K.
dc.contributor.authorSachdev, Vibhu
dc.contributor.authorKleinstiver, Benjamin P.
dc.contributor.authorTaylor-Parker, Julian
dc.contributor.authorWelch, Moira M.
dc.contributor.authorHu, Yiheng
dc.contributor.authorSalgia, Ravi
dc.contributor.authorParvin, Jeffrey D.
dc.contributor.authorOzonoff, Al
dc.contributor.authorRameh, Lucia E.
dc.contributor.authorJoung, J. Keith
dc.contributor.authorBharti, Ajit K.
dc.contributor.authorWhite, Forest M.
dc.date.accessioned2017-06-16T15:15:36Z
dc.date.available2017-06-16T15:15:36Z
dc.date.issued2017-03
dc.date.submitted2017-02
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/1721.1/109949
dc.description.abstractProteasomal degradation of topoisomerase I (topoI) is one of the most remarkable cellular phenomena observed in response to camptothecin (CPT). Importantly, the rate of topoI degradation is linked to CPT resistance. Formation of the topoI-DNA-CPT cleavable complex inhibits DNA re-ligation resulting in DNA-double strand break (DSB). The degradation of topoI marks the first step in the ubiquitin proteasome pathway (UPP) dependent DNA damage response (DDR). Here, we show that the Ku70/Ku80 heterodimer binds with topoI, and that the DNA-dependent protein kinase (DNA-PKcs) phosphorylates topoI on serine 10 (topoI-pS10), which is subsequently ubiquitinated by BRCA1. A higher basal level of topoI-pS10 ensures rapid topoI degradation leading to CPT resistance. Importantly, PTEN regulates DNA-PKcs kinase activity in this pathway and PTEN deletion ensures DNA-PKcs dependent higher topoI-pS10, rapid topoI degradation and CPT resistance.en_US
dc.language.isoen_US
dc.publisherImpact Journals/National Center for Biotechnology Information (U.S.)en_US
dc.relation.isversionofhttp://dx.doi.org/10.18632/oncotarget.16376en_US
dc.rightsCreative Commons Attribution 3.0 Unported licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/en_US
dc.sourceImpact Journalsen_US
dc.titleCamptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathwayen_US
dc.typeArticleen_US
dc.identifier.citationAndo, Koji; Shah, Ankur K.; Sachdev, Vibhu; Kleinstiver, Benjamin P.; Taylor-Parker, Julian; Welch, Moira M.; Hu, Yiheng et al. “Camptothecin Resistance Is Determined by the Regulation of Topoisomerase I Degradation Mediated by Ubiquitin Proteasome Pathway.” Oncotarget (November 2015): 16376en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorWhite, Forest M
dc.relation.journalOncotargeten_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsAndo, Koji; Shah, Ankur K.; Sachdev, Vibhu; Kleinstiver, Benjamin P.; Taylor-Parker, Julian; Welch, Moira M.; Hu, Yiheng; Salgia, Ravi; White, Forest M.; Parvin, Jeffrey D.; Ozonoff, Al; Rameh, Lucia E.; Joung, J. Keith; Bharti, Ajit K.en_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-1545-1651
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record